Literature DB >> 34862326

Childhood strokes in China describing clinical characteristics, risk factors and performance indicators: a case-series study.

Yaxian Deng1, Gaifen Liu2, Guitao Zhang3, Juanyu Xu4, Chunmei Yao4, Lei Wang4, Chengsong Zhao5, Yongjun Wang3.   

Abstract

AIM: To investigate clinical characteristics, risk factors (RFs), neurologic deficits and medical care provided in children who had a stroke in China.
METHODS: We conducted a retrospective case-series study using the medical records of children aged 1 month to 18 years with arterial ischaemic stroke (AIS) or haemorrhagic stroke (HS) (with the entry codes I60, I61, I62, I63 (ICD-10)), who were admitted to different hospitals in Beijing, between January 2018 and December 2018. We obtained the following information from the charts: demographic characteristics, clinical presentations, RFs for paediatric stroke, laboratory examination, neuroimaging records and neurologic sequelae.
RESULTS: We identified 312 first admissions for stroke (172 AIS and 140 HS). The mean age at onset was 8.6±3.9 years for patients who had an AIS and 8 (5-13) years for patients who had an HS. There were more males than females in both groups (AIS: 59.88% vs 40.12%; HS: 52.14% vs 47.86%). A known aetiology was identified in 92.44% and 86.43% of patients who had an AIS and HS, respectively. The leading cause of AIS was cerebrovascular diseases including moyamoya (68.6%), while that for HS was arteriovenous malformation (51.43%). The most common initial clinical presentation was hemiplegia (86.05%) in patients who had an AIS and headache (67.86%) in patients who had an HS. The use of healthcare, including acute treatment (antithrombotic in 17.44%, anticoagulant in 5.23%) and secondary prevention (antithrombotic in 6.39%, anticoagulant in 1.16%), varied and was significantly lower among patients who had an AIS. The most common complications were epilepsy (22.09%) and pneumonia (4.65%) in patients who had an AIS and epilepsy (17.14%) and hydrocephalus (12.14%) in patients who had an HS. Neurological deficits occurred in 62.8% of patients who had an AIS and 72.86% of patients who had an HS.
CONCLUSION: Cerebral arteriopathy was a major RF for both AIS and HS in children living in China. Large epidemiological studies are required to identify RFs to prevent stroke as well as appropriate interventions. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  paediatrics; stroke

Mesh:

Substances:

Year:  2021        PMID: 34862326      PMCID: PMC9067266          DOI: 10.1136/svn-2021-001062

Source DB:  PubMed          Journal:  Stroke Vasc Neurol        ISSN: 2059-8696


Introduction

Stroke is defined as a sudden-onset, focal neurologic deficit resulting from irreversible, focal, ischaemic/haemorrhagic damage to the brain parenchyma secondary to a cerebrovascular disorder. Although stroke in children is rare, with an incidence rate of 3–25 per 100 000 children per year in developed countries, it is among the top 10 causes of death in children. Stroke causes significant morbidity and mortality, which result in a larger burden on family and society.1–3 Although important similarities probably exist between stroke in young adults and that in adolescents, virtually all aspects of stroke in older adults are different from those in children. Atherosclerosis and accompanying modifiable risk factors (RFs) that dominate adult stroke mechanisms and treatment are nearly non-existent in paediatric stroke. In the past few years, many important advances in paediatric stroke research and management have been made, offering hope of evidence-based medical advice on treatment; however, paediatricians have an insufficient level of awareness, resulting in delayed diagnosis, less experience in the use of acute antithrombotic or anticoagulant treatment and secondary prevention, including thrombolysis or thrombectomy. The aim of this study was to provide data on the clinical presentations, RFs for paediatric stroke and to reflect the medical care situation in paediatric stroke regarding work-up and acute treatment, by reviewing the clinical data from hospitals in Beijing. To our knowledge, no multicentre study has yet assessed the clinical characteristics and the use of performance indicators in paediatric stroke in China.

Methods

Patient population

We reviewed the charts of all inpatients between January 2018 and December 2018 with the entry codes I60, I61, I62 I63 (ICD-10, The International Statistical Classification of Diseases and Related Health Problems 10th Revision) from different hospitals in Beijing. All patients aged between 1 month and 18 years with a diagnosis of arterial ischaemic stroke (AIS) or haemorrhagic stroke (HS) (including intracerebral haemorrhage and subarachnoid haemorrhage) were included in our review. Exclusion criteria were (presumed) presence of perinatal/neonatal stroke, cerebral venous sinus thrombosis and transient ischaemic attack.

Collected data

For each patient, the following data were collected: Demographics: age at admission, gender and race. RFs: data on RFs for paediatric stroke were collected and assigned into 10 predetermined categories based on the International Pediatric Stroke Study (IPSS) definitions: arteriopathy (any arterial abnormality on vascular imaging other than isolated vessel occlusion), cardiac disorders, chronic systemic conditions, infection, acute head and neck disorders, acute systemic conditions, prothrombotic states (PTSs), chronic head and neck disorders, atherosclerosis-related RFs, other RFs and unknown. Presentation: onset-to-door time, mode of presentation at onset including focal signs (hemiparesis, facial paralysis, visual or speech disturbance, numbness of limb, dysphagia and dizziness), diffuse signs (decreased level of consciousness and headache) and seizures. Laboratory and auxiliary investigations: complete blood cell count, blood biochemical test, blood homocysteine, C reactive protein, lupus anticoagulant, anticardiolipin antibody and transthoracic echocardiogram. Radiographic characteristics: involved vascular territory (anterior or posterior circulation or both) and laterality (unilateral or bilateral) were analysed. Performance indicators: we selected part of the key performance indicators developed by the Get With the Guidelines-Stroke programme: (1) acute performance measures: thrombolytic therapy and early antithrombotic therapy or anticoagulant and (2) discharge performance measures: antithrombotic therapy and anticoagulation.

Clinical outcomes

The outcomes including complication, neurologic sequelae were assessed at discharge. The neurologic sequelae included movement disorder, aphasia, hearing disorder, vision deficits, cognitive disorder, feeling disorder, memory disorder and epilepsy.

Statistical analysis

Patients were categorised into four groups: infant (<1 year), preschool year (1–5 years), school year (6–12 years) and adolescent (13–18 years). Baseline characteristics including gender, age at stroke onset, RFs, presenting symptoms (focal signs, diffuse sings and epilepsy) and imaging characteristics were described in the IS and HS groups separately. The proportion of children with each RF was calculated for all children. Continuous variables were described as mean±SD if normally distributed or as median and IQR if it is not normally distributed. Categorical variables are presented as absolute numbers with percentages. Statistical analysis was performed using a commercially available software package (SPSS V.19.0).

Results

Population characteristics

In total, 312 patients were included; 172 patients (55.1% of the whole series) had AIS and 140 (44.9%) had HS. Demographic characteristics and clinical presentation of children who had an AIS or HS (including mean age at stroke onset, sex ratio, distribution of age and mode of presentation) are shown in table 1. For AIS, the peak distribution ages were between 1–5 years and 6–12 years and 103 children were males (M:F=1.49). For HS, the peak distribution ages were between 6–12 years and 13–18 years; 73 children were males (M:F=1.09).
Table 1

Demographic characteristics and the presentation of children who had a stroke

CharacteristicNo. (%)
AISHS
Gender, male103 (59.88)73 (52.14)
Mean age at onset (years)8.6±3.98.00 (5.00, 13.00)
Age at stroke, mean (SD)
Distribution of age (years)
 <12 (1.16)5 (3.57)
 1–540 (23.26)35 (25.00)
 6–1299 (57.56)62 (44.29)
 13–1831 (18.02)38 (27.14)
Mode of presentation
Focal signs
 Hemiparesis148 (86.05)43 (30.71)
 Facial paralysis1 (0.58)0 (0)
 Hemiparesis and facial paralysis12 (6.98)0 (0)
 Speech disturbance43 (25.29)16 (11.43)
 Visual disturbance9 (5.29)10 (7.14)
 Numbness of limb29 (17.06)11 (7.86)
 Dysphagia6 (3.55)4 (2.86)
 Dizziness12 (7.02)27 (19.29)
Diffuse signs
 Decreased level of consciousness16 (9.47)43 (30.71)
 Headache36 (21.18)95 (67.86)
 Seizures29 (17.16)24 (17.14)
Laterality (only AIS)
 Unilateral117 (68.02)
 Bilateral44 (25.58)

AIS, arterial ischaemic stroke.

Demographic characteristics and the presentation of children who had a stroke AIS, arterial ischaemic stroke.

Presenting symptoms

Table 1 shows the presenting symptoms for all patients who had an AIS and HS. Focal symptoms, in particular acute hemiparesis, including facial paralysis, were the most common presenting symptoms in patients who had an AIS. Non-specific symptoms, such as headache and decreased level of consciousness, were observed in 21.18% and 9.47% of the patients, respectively; 17.16% children presented with seizures. For HS, non-specific symptoms such as headache and decreased level of consciousness were the most common presenting features. The rate of seizures in patients who had an AIS was similar to that in patients who had an HS. Bilateral ischaemia occurs in 26.58% patients.

Aetiologies and RFs

A known RF was identified in 92.44% and 86.43% of patients who had an AIS and HS. The leading causes were arteriopathies including moyamoya (118 patients) and dissection (5 patients) for AIS and arteriovenous malformation (AVM) and cavernous malformation (CM) for HS. Cardiac diseases only occurred in 14 patients. A detailed overview of the described RFs is shown in table 2.
Table 2

Risk factors (RFs) of patients who had an AIS and HS

RFsAISHS
NumberPer centNumberPer cent
Arteriopathy140
 Moyamoya11868.6085.71
 Dissection52.9110.71
 Vasculitis74.0721.43
 PVA10.5800
 Peripheral vascular disease10.5800
 AVM007251.43
 CM002820.00
 Aneurysm0064.29
 AVF0032.14
 Venous malformation of scalp0000
 Angiotelectasis10.5800
Cardiac disorders
 ASD10.5800
 VSD21.1600
 RHD10.5810.71
 Arrhythmia21.1600
 Hypertension21.1642.86
 KD10.580
 PDA10.5810.71
 Endocarditis10.5810.71
 DCM10.5800
 PFO10.5800
 Pulmonary artery stenosis10.5800
Chronic head and neck disorders
 Cerebral tumour21.1642.86
 Ventriculoperitoneal shunt0010.71
 Sturge-Weber syndrome0000
Acute head and neck disorders
 Nasosinusitis95.2300
 Mastoiditis10.5800
 Brain trauma42.3332.14
Chronic systemic conditions
 Connective tissue disease31.7400
 Iron-deficiency anaemia10.5800
 Down syndrome10.5800
 MELAS52.9100
Prothrombotic states0000
Acute systemic conditions
 Fever>48 hours10.5810.71
Unknown137.561913.57

AIS, arterial ischaemic stroke; ASD, atrial septal defect; AVF, arteriovenous fistula; AVM, arteriovenous malformation; CM, cavernous malformation; DCM, dilated cardiomyopathy; HS, haemorrhagic stroke; KD, Kawasaki disease; MELAS, mitochondrial encephalopathy with lactic acidosis and stroke-like episodes; PDA, patent ductus arteriosus; PFO, patent foramen ovale; PVA, postvaricella arteriopathy; RHD, rheumatic heart disease; VSD, ventricular septal defect.

Risk factors (RFs) of patients who had an AIS and HS AIS, arterial ischaemic stroke; ASD, atrial septal defect; AVF, arteriovenous fistula; AVM, arteriovenous malformation; CM, cavernous malformation; DCM, dilated cardiomyopathy; HS, haemorrhagic stroke; KD, Kawasaki disease; MELAS, mitochondrial encephalopathy with lactic acidosis and stroke-like episodes; PDA, patent ductus arteriosus; PFO, patent foramen ovale; PVA, postvaricella arteriopathy; RHD, rheumatic heart disease; VSD, ventricular septal defect. We analysed the proportion of patients according to age, clinical presentations, gender and dysfunction after stroke in patients who had an AIS resulting from moyamoya and in those who had an HS resulting from AVM or CM (figure 1). We also analysed the proportion of RFs, clinical presentation and neurological deficits according to different age groups (figure 2).
Figure 1

Proportion of age, clinical presentation, gender and dysfunction after stroke in AIS resulting from moyamoya (A, B and G), HS resulting from AVM (C, D and G) or CM (E, F and G).

Figure 2
Proportion of age, clinical presentation, gender and dysfunction after stroke in AIS resulting from moyamoya (A, B and G), HS resulting from AVM (C, D and G) or CM (E, F and G).

Performance indicators and complications

None of the patients received hyperacute therapy (thrombolysis or mechanical thrombectomy). Diagnostic work-ups in hypertension, hyperlipidemia and diabetes were rarely applied. Among patients who had an AIS, the proportions of those who used antithrombotic and anticoagulation use were 17.44% and 5.23%, respectively. Additionally, among patients who had an AIS, aspirin was administered at discharge in 5.23% patients, clopidogrel in 1.16% patients and warfarin in 1.16% patients. Epilepsy was the most common complication in both the ischaemic and HS groups. Neurological deficits occurred in 62.8% of patients who had an AIS and 72.86% of patients who had an HS. Performance indicators, complications on discharge and neurologic deficits in patients who had an AIS or HS are shown in table 3.
Table 3

Examination, performance indicators and complications on discharge of patients who had an AIS and HS

IndicatorsASHS
NumberPer centNumberPer cent
TTE examination5733.14139.29
Abnormal TTE12/5721.0517.69
Bubble study52.9100
Positive bubble study2/540.0000
TCD examination126.9821.42
Examination of CT scan of the brain14785.4713395.00
MRI examination of the brain16294.1912589.29
MRA examination of the brain6437.21148.57
CTA of the head7744.771810.00
DSA of the head12552.908359.28
Abnormal DSA121/12596.866/8379.51
Acute treatment
 Thrombolysis00
 Antithrombotic3017.44
 Anticoagulant95.23
 Neuroprotective agents5029.072215.71
 Antiepileptic drug9354.075337.86
Discharge medication
 Antithrombotic
 Aspirin95.23
 Clopidogrel21.16
 Anticoagulant
 Warfarin21.16
 Antiepileptic drug3822.092417.14
Complication
 Epilepsy3822.092417.14
 Hydrocephalus001712.14
 Deep venous thrombus0000
 Pneumonia84.65139.29
 Cerebral hernia0032.14
 Infection of CNS21.1664.29
 Electrolyte disturbance10.58139.29
 Neurological deficits
 Movement7744.775942.14
 Speech137.5611
 hearing10.5810.71
 Vision42.3342.86
 Cognitive52.9121.43
 Epilepsy3822.092417.14
 Feelling10.5810.71
 Memory0000

AIS, arterial ischaemic stroke; CNS, central nervous system; CTA, computed tomographic angiography; DSA, digital angiography; HS, haemorrhagic stroke; MRA, magnetic resonance angiography; TCD, transcranial Doppler; TTE, transthoracic echocardiogram.

Examination, performance indicators and complications on discharge of patients who had an AIS and HS AIS, arterial ischaemic stroke; CNS, central nervous system; CTA, computed tomographic angiography; DSA, digital angiography; HS, haemorrhagic stroke; MRA, magnetic resonance angiography; TCD, transcranial Doppler; TTE, transthoracic echocardiogram.

Discussion

Paediatric stroke is a severe condition, with potentially devastating consequences such as development (motor, language and mentality) and behavioural disabilities or epilepsy.4 Awareness about initial symptoms, using MRI first and adapted management in the acute phase, individualised thrombolysis or recanalisation treatment strategies, antithrombotic and anticoagulation therapy are the key elements to improve paediatric management and outcomes.5 Our study provides multicentre data of children who had an AIS and HS and to some extent reflected the current medical care situation in paediatric stroke in China. The result regarding sex ratio was similar to that reported in the literature.6 Both ischaemic stroke and HS were more common among males than among females.6 The most common presenting symptom among patients who had an AIS was acute focal neurological deficit, which was consistent with the literature reports.6 Seizures occurred in 17.16% cases, which was consistent with Silverman and Zelano’s7 8 reports that poststroke seizures occurred in 5%–20%, but lower than Polat et al’s9 report (59% patients). Regarding RFs, in our study, arteriopathy (85.47%) and cardiac diseases (8.14%) were the most common RFs for AIS. The ratio of RF of cerebral arteriopathy for AIS was higher than that in some researches. However, recent studies have also reported that children arteriopathy was the most common identifiable cause of AIS, accounting for up to 60%–80% of cases in previously healthy children, and it was reported to be the strongest predictor of recurrent events.10 11 In a previous study, the most common causes of intracranial arterial steno-occlusive disease in children were 12 and this finding is consistent with that of our study. Traumatic craniocervical arterial dissection, especially carotid artery dissection, was a common cause of cerebrovascular injuries in children, accounting for approximately 20% of paediatric acute ischaemic strokes which was higher than that reported in our study (2.91%).13 In children presenting with posterior circulations strokes, dissection of the vertebral artery should always be considered in the differential consideration.14 Data from the IPSS showed that cardiac diseases are the primary cause of AIS, accounting for 28%15 which was higher than our result (8.14%). PTSs were not found in our cases. However, the literature reported that thromboembolic causes accounted for 20%–30% of causes of paediatric AIS.5 The low ratio may be related to insufficient haematological examination in our cases. Several recommendations have been published concerning aetiological work-up in paediatric AIS and the authors proposed the following investigations: comprehensive clinical evaluation, haematological investigations, biochemistry tests, thrombophilia testing, inflammation and infection tests and cardiovascular evaluation.16 RFs for HS were mainly AVM and CM and this result is consistent with previous reports.17 18 The time delay in onset-to-door time, door-to-imaging time and door-to-needle time is a well-known barrier in paediatric stroke care, which may prevent time-critical treatments such as thrombolysis or mechanical thrombectomy.19 In our cohort, onset-to-door time was significantly prolonged. Onset-to-door time of less than 24 hours was observed in 14.4% of patients who had an HS and in 3.7% of patients who had an AIS. Onset-to-door time delay in our patients may be related to the aetiologies, as AIS was more likely to be caused by moyamoya in our study. Although, several studies have shown that endovascular clot retrieval and thrombolysis in adult stroke and in some children have excellent results.20–29 In our study, no thrombolysis or mechanical thrombectomy was used and antithrombotic and anticoagulation use was only observed in 17.44% and 5.23% of patients who had an AIS. The low rate of thrombolysis and antithrombotic use may be related to delayed hospital visit and delayed diagnosis. Moreover, the lack of awareness for paediatric stroke, more stroke-mimicking diseases as well as insufficient paediatric stroke attention may be mainly responsible for this unsatisfactory situation. In order to decrease time of onset to diagnosis and decision making, apart from increasing awareness, there should be considerable effort invested into improving clinical pathways including establishment of paediatric acute stroke centres and standardised protocol for evaluation and treatment of stroke. In recent years, some methods of evaluation and classification of ischaemic stroke in children have been developed such as modified paediatric version of the Alberta Stroke Program Early CT Score using acute MRI,30 the Childhood AIS Standardized Classification And Diagnostic Evaluation criteria31 and the paediatric version of the National Institutes of Health Stroke Scale32; however, these methods are not universally used. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines and the American Heart Association Stroke Council and the Council on Cardiovascular Disease have also developed an expert consensus on the diagnosis and treatment of stroke in children33 34; however, it has not been effectively applied to clinical treatment. In terms of long-term outcomes, children and young people do not necessarily recover better than adults from stroke. Mosch et al 35 demonstrated that children and adults matched for infarct site had similar levels of impairment. Pavlovic et al reported that up to two-thirds of patients experience lifelong neurological or cognitive sequelae.15 36 Hemiparesis is one of the most common long-term neurological consequences. It has been reported in over half of the children in a previous study.37 However, there are few outcome measure assessment tools for paediatric stroke. The paediatric stroke outcome measure is a standardised neurological examination/impairment level assessment tool, specifically validated in infants (≤2 years of age) and in children and young people (2–16 years) who had an AIS. Outcomes are highly variable with regard to the field of outcomes tested and aetiology of stroke. Data from the IPSS including more than 600 children who had an AIS reported residual impairments in 74% of them.38 Most studies estimate that over 50%–70% of patients who had a paediatric stroke will have long-lasting or persistent neurological deficits or develop subsequent cognitive, learning, seizure disorders or developmental problems.15 39

Strength and limitations of the study

There are some advantages of the study design. First is the multicentre design and the relatively large sample size. Second, recruiting patients from different hospitals may improve the generalisability to some extent compared with single-centre study. There are a few limitations to the study. First, only several hospitals were included in the study and there maybe inclusion bias. Second, the study was retrospective and the data may be incomplete.

Conclusion

Arteriopathy was the most common RF in patients who had an AIS, accounting for 85.47%, while cardiac diseases were seldom reported and prothrombotic state was not observed in our study as RFs. AVM and CM were the most common causes of HS. The use of healthcare was significantly lower in all patients who had an AIS including acute treatment and discharge medication use. Ultimately, large epidemiological studies are required to identify RFs to prevent stroke as well as appropriate interventions.
  39 in total

1.  Arterial ischemic stroke in infants, children, and adolescents: results of a Germany-wide surveillance study 2015-2017.

Authors:  Lucia Gerstl; Raphael Weinberger; Florian Heinen; Michaela V Bonfert; Ingo Borggraefe; A Sebastian Schroeder; Moritz Tacke; Mirjam N Landgraf; Katharina Vill; Karin Kurnik; Anna-Lisa Sorg; Martin Olivieri
Journal:  J Neurol       Date:  2019-08-23       Impact factor: 4.849

Review 2.  Primary versus secondary mechanical thrombectomy for anterior circulation stroke in children: An update.

Authors:  Manuel Cappellari; Giuseppe Moretto; Andrea Grazioli; Giuseppe Kenneth Ricciardi; Paolo Bovi; Elisa Francesca Maria Ciceri
Journal:  J Neuroradiol       Date:  2017-12-19       Impact factor: 3.447

Review 3.  Arterial ischemic stroke in non-neonate children: Diagnostic and therapeutic specificities.

Authors:  M Kossorotoff; S Chabrier; K Tran Dong; S Nguyen The Tich; M Dinomais
Journal:  Rev Neurol (Paris)       Date:  2019-06-08       Impact factor: 2.607

4.  Endovascular clot retrieval for acute ischaemic posterior circulation stroke in children: a new effective therapy?

Authors:  Adam Rennie
Journal:  Dev Med Child Neurol       Date:  2020-02-24       Impact factor: 5.449

5.  Endovascular treatment of stroke in children under 2 years with heart failure and ventricular assist device.

Authors:  Elvira Jiménez Gómez; Isabel Bravo Rey; Rafael Oteros Fernández; Fernando Delgado Acosta
Journal:  Interv Neuroradiol       Date:  2019-05-09       Impact factor: 1.610

Review 6.  Risk Factors of Post-Stroke Epilepsy in Children; Experience from a Tertiary Center and a Brief Review of the Literature.

Authors:  İpek Polat; Uluç Yiş; Müge Ayanoğlu; Derya Okur; Pınar Edem; Cem Paketçi; Erhan Bayram; Semra Hız Kurul
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-11-13       Impact factor: 2.136

7.  Low-dose tissue plasminogen activator thrombolysis in children.

Authors:  Michael Wang; Taru Hays; Vinod Balasa; Rochelle Bagatell; Ralph Gruppo; Eric F Grabowski; Leonard A Valentino; George Tsao-Wu; Marilyn J Manco-Johnson
Journal:  J Pediatr Hematol Oncol       Date:  2003-05       Impact factor: 1.289

8.  Prevalence of Symptoms of Anxiety, Depression, and Post-traumatic Stress Disorder in Parents and Children Following Pediatric Stroke.

Authors:  Laura L Lehman; Kristin Maletsky; Jeanette Beaute; Kshitiz Rakesh; Kush Kapur; Michael J Rivkin; Christine Mrakotsky
Journal:  J Child Neurol       Date:  2020-03-23       Impact factor: 1.987

9.  Diagnosis of vertebral artery dissection in childhood posterior circulation arterial ischaemic stroke.

Authors:  Nadine McCrea; Dawn Saunders; Emmanouil Bagkeris; Manali Chitre; Vijeya Ganesan
Journal:  Dev Med Child Neurol       Date:  2015-10-26       Impact factor: 5.449

10.  Lack of progressive arteriopathy and stroke recurrence among children with cryptogenic stroke.

Authors:  Stephane Darteyre; Stephane Chabrier; Emilie Presles; Alain Bonafé; Agathe Roubertie; Bernard Echenne; Nicolas Leboucq; Francois Rivier
Journal:  Neurology       Date:  2012-11-28       Impact factor: 9.910

View more
  2 in total

Review 1.  Causes and Risk Factors of Pediatric Spontaneous Intracranial Hemorrhage-A Systematic Review.

Authors:  Urszula Maria Ciochon; Julie Bolette Brix Bindslev; Christina Engel Hoei-Hansen; Thomas Clement Truelsen; Vibeke Andrée Larsen; Michael Bachmann Nielsen; Adam Espe Hansen
Journal:  Diagnostics (Basel)       Date:  2022-06-13

2.  Epidemiology of Moyamoya Angiopathy in Eastern India.

Authors:  Shambaditya Das; Souvik Dubey; Suman Das; Avijit Hazra; Alak Pandit; Ritwik Ghosh; Biman Kanti Ray
Journal:  Front Neurol       Date:  2022-03-04       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.